PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 20260 citationsOpen Access

The Combined Use of Hydroxymethylbutyrate and Branched-Chain Amino Acids to Counteract Uremic Sarcopenia

View Full Paper
GMGiulia MarroneMLManuela Di LauroKCKevin Cornali

Key Points

  • This study aims to assess the impact of a special food product on muscle wasting and inflammation in hemodialysis patients.
  • Randomized double-blind crossover design involving 24 adult hemodialysis patients.
  • Participants received supplementation of the special food product or placebo for 12 weeks.
  • Outcomes measured included muscle thickness, body composition, inflammatory markers, and quality of life.
  • Significant increases in quadriceps rectus femoris thickness and fat-free mass percentage.
  • Reductions in oxidative stress and inflammatory biomarkers were noted.
  • Quality of life improvements in energy/fatigue and general health domains.

Abstract

Background: Hemodialysis (HD) patients frequently develop muscle wasting and chronic inflammation, conditions associated with functional decline and reduced quality of life (QoL). Nutritional strategies that provide targeted anabolic support without increasing nitrogen load may offer clinical benefits. The aim of this study was to evaluate the possible impact of a food for special medical purposes (FFSMP), composed of free-form branched-chain amino acids, β-hydroxy-β-methylbutyrate, and zinc, on muscle mass and strength, laboratory parameters, physical performance (PP), and QoL in HD patients. Methods: in this randomized double-blind crossover study, 24 adult HD patients received the FFSMP (10 g/day; two sachets) supplementation or placebo for 12 weeks, separated by an 8-week wash-out (protocol code RS 29.23). Measured outcomes included quadriceps rectus femoris thickness (QRFT) muscle, body composition analysis, inflammatory markers, oxidative stress indices, other routine biochemical parameters, PP, and QoL (SF-36 questionnaire). Results: FFSMP supplementation resulted in significant increases in QRFT and in fat-free mass percentage. Reductions in oxidative stress and inflammatory biomarkers were observed. Routine biochemical parameters remained stable, with the exception of a decrease in pre-dialysis urea. Functional performance measures did not differ between treatment periods. Improvements were noted in selected SF-36 domains, specifically energy/fatigue and general health. No major adverse events occurred during the study. Conclusions: In HD patients, this FFSMP produced favorable changes in markers of muscle mass and systemic inflammation without affecting short-term physical performance. These findings support the potential clinical utility of targeted amino acid supplementation in this patient population, highlighting the need for larger, longer-term trials.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Marrone et al. (2026) studied this question.

synapsesocial.com/papers/6980ffa4c1c9540dea81253chttps://doi.org/10.3390/nu18030483
Ask AI
Helpful
Bookmark
Share
View Full Paper